BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 17080381)

  • 21. Risk factors of nosocomial infection with extended-spectrum beta-lactamase-producing bacteria in a neonatal intensive care unit in China.
    Huang Y; Zhuang S; Du M
    Infection; 2007 Oct; 35(5):339-45. PubMed ID: 17721736
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increasing Incidence of Extended-Spectrum β-Lactamase-Producing Escherichia coli in Community Hospitals throughout the Southeastern United States.
    Thaden JT; Fowler VG; Sexton DJ; Anderson DJ
    Infect Control Hosp Epidemiol; 2016 Jan; 37(1):49-54. PubMed ID: 26458226
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae on the outcome of community-onset bacteremic urinary tract infections.
    Yang YS; Ku CH; Lin JC; Shang ST; Chiu CH; Yeh KM; Lin CC; Chang FY
    J Microbiol Immunol Infect; 2010 Jun; 43(3):194-9. PubMed ID: 21291846
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative effectiveness of flomoxef versus carbapenems in the treatment of bacteraemia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae with emphasis on minimum inhibitory concentration of flomoxef: a retrospective study.
    Lee CH; Su LH; Chen FJ; Tang YF; Li CC; Chien CC; Liu JW
    Int J Antimicrob Agents; 2015 Dec; 46(6):610-5. PubMed ID: 26387064
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Phenotypic and molecular identification of extended-spectrum beta-lactamase (ESBL) TEM and SHV produced by clinical isolates Escherichia coli and Klebsiella spp. in hospitals].
    González Mesa L; Ramos Morí A; Nadal Becerra L; Morffi Figueroa J; Hernández Robledo E; Alvarez AB; Marchena Bequer JJ; González Alemán M; Villain Plous C
    Rev Cubana Med Trop; 2007; 59(1):52-8. PubMed ID: 23427419
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Extended-spectrum beta-lactamase-producing phenotype signifies a poor prognosis for patients with cefpodoxime-resistant Escherichia coli or Klebsiella pneumoniae bacteremia.
    Lee CI; Lee NY; Yan JJ; Lee HC; Ko NY; Chang CM; Wu CJ; Chen PL; Wang LR; Ko WC
    J Microbiol Immunol Infect; 2009 Aug; 42(4):303-9. PubMed ID: 19949753
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical and microbiologic analysis of a hospital's extended-spectrum beta-lactamase-producing isolates over a 2-year period.
    Burgess DS; Hall RG; Lewis JS; Jorgensen JH; Patterson JE
    Pharmacotherapy; 2003 Oct; 23(10):1232-7. PubMed ID: 14594340
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An observational study on bloodstream extended-spectrum beta-lactamase infection in critical care unit: incidence, risk factors and its impact on outcome.
    Nasa P; Juneja D; Singh O; Dang R; Singh A
    Eur J Intern Med; 2012 Mar; 23(2):192-5. PubMed ID: 22284253
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rise of community-onset urinary tract infection caused by extended-spectrum β-lactamase-producing Escherichia coli in children.
    Fan NC; Chen HH; Chen CL; Ou LS; Lin TY; Tsai MH; Chiu CH
    J Microbiol Immunol Infect; 2014 Oct; 47(5):399-405. PubMed ID: 23834784
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical and economic impact of bacteremia with extended- spectrum-beta-lactamase-producing Enterobacteriaceae.
    Schwaber MJ; Navon-Venezia S; Kaye KS; Ben-Ami R; Schwartz D; Carmeli Y
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1257-62. PubMed ID: 16569837
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical and molecular epidemiology of community-onset, extended-spectrum beta-lactamase-producing Escherichia coli infections in Thailand: a case-case-control study.
    Apisarnthanarak A; Kiratisin P; Saifon P; Kitphati R; Dejsirilert S; Mundy LM
    Am J Infect Control; 2007 Nov; 35(9):606-12. PubMed ID: 17980240
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors of mortality from community-onset bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae.
    Apisarnthanarak A; Kiratisin P; Mundy LM
    Infect Control Hosp Epidemiol; 2008 Jul; 29(7):671-4. PubMed ID: 18624669
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Extended spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae isolated in a rural hospital.
    Basak S; Mallick SK; Bose S
    J Indian Med Assoc; 2009 Dec; 107(12):855-8. PubMed ID: 20509468
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Extended spectrum beta lactamase producing organisms causing urinary tract infections in Sri Lanka and their antibiotic susceptibility pattern -A hospital based cross sectional study.
    Fernando MM; Luke WA; Miththinda JK; Wickramasinghe RD; Sebastiampillai BS; Gunathilake MP; Silva FH; Premaratna R
    BMC Infect Dis; 2017 Feb; 17(1):138. PubMed ID: 28187754
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Infections due to Escherichia coli producing extended-spectrum beta-lactamase among hospitalised patients: factors influencing mortality.
    Peña C; Gudiol C; Calatayud L; Tubau F; Domínguez MA; Pujol M; Ariza J; Gudiol F
    J Hosp Infect; 2008 Feb; 68(2):116-22. PubMed ID: 18226420
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Integrating rapid diagnostics and antimicrobial stewardship improves outcomes in patients with antibiotic-resistant Gram-negative bacteremia.
    Perez KK; Olsen RJ; Musick WL; Cernoch PL; Davis JR; Peterson LE; Musser JM
    J Infect; 2014 Sep; 69(3):216-25. PubMed ID: 24841135
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment with fluoroquinolones or with beta-lactam-beta-lactamase inhibitor combinations is a risk factor for isolation of extended-spectrum-beta-lactamase-producing Klebsiella species in hospitalized patients.
    Wener KM; Schechner V; Gold HS; Wright SB; Carmeli Y
    Antimicrob Agents Chemother; 2010 May; 54(5):2010-6. PubMed ID: 20211888
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The efficacy of non-carbapenem antibiotics for the treatment of community-onset acute pyelonephritis due to extended-spectrum β-lactamase-producing Escherichia coli.
    Park SH; Choi SM; Chang YK; Lee DG; Cho SY; Lee HJ; Choi JH; Yoo JH
    J Antimicrob Chemother; 2014 Oct; 69(10):2848-56. PubMed ID: 24928854
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk factors for infection and treatment outcome of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in patients with hematologic malignancy.
    Kang CI; Chung DR; Ko KS; Peck KR; Song JH;
    Ann Hematol; 2012 Jan; 91(1):115-21. PubMed ID: 21556875
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in spanish hospitals (GEIH-BLEE Project 2002)].
    Hernández JR; Pascual A; Cantón R; Martínez-Martínez L;
    Enferm Infecc Microbiol Clin; 2003 Feb; 21(2):77-82. PubMed ID: 12586030
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.